ArticleMayo Clinic proceedings2026
Cardiovascular Health and Outcomes in Carriers With Genetic Variants of Hypertrophic Cardiomyopathy.
Article in Mayo Clinic proceedings, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A multiancestry polygenic risk score improves stratification in patients with hypertrophic cardiomyopathy.Nature cardiovascular research · 2026Pooled it
- Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo elucidate the interplay between genetic predisposition and cardiovascular health (CVH) factors in individuals with pathogenic or likely pathogenic variants in hypertrophic cardiomyopathy sarcomere-encoding genes (SARC-HCM-P/LP).
methodsThis retrospective cohort study used data from the UK Biobank, including 159,375 participants aged 40 to 69 years with whole exome sequencing data and no baseline cardiovascular disease. Participants were stratified into 2 groups based on the presence of SARC-HCM-P/LP variants (SARC-HCM-P/LP vs SARC-NEG). Cardiovascular health was assessed by the Life's Essential 8 score, categorizing participants into favorable, intermediate, and unfavorable CVH profiles. The primary outcome was a composite of heart failure, arrhythmias, and cardiovascular mortality. Adjusted Cox models examined the association between genetic variant status, CVH, and risk of adverse cardiovascular outcomes.
resultsOf 159,375 participants, 446 were SARC-HCM-P/LP carriers (median age, 56 years; 47.3% male). The median Life's Essential 8 score was similar between SARC-HCM-P/LP and SARC-NEG groups (68.1 vs 66.9; P=.36). Compared with SARC-NEG carriers with favorable CVH, the risk of the primary outcome was higher in SARC-NEG carriers with intermediate (adjusted hazard ratio [HR
conclusionSARC-HCM-P/LP carriers remain at elevated cardiovascular risk despite favorable CVH, highlighting the significant role of genetics in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.